Even with 269 million lipid-lowering prescriptions written in the United States over the past twelve months, roughly 30 million adults remain above their risk-based LDL-C targets, and that stubborn gap is precisely what CHMP’s positive opinion on obicetrapib is designed to address. The Committee for Medicinal Products for Human Use recommended marketing authorization on July 24 for both Ubeslo (obicetrapib 10 mg monotherapy) and Evlarco (obicetrapib 10 mg plus ezetimibe 10 mg fixed-dose combination), covering primary hypercholesterolemia and mixed dyslipidemia across the EU, Iceland, Liechtenstein, and Norway. The European Commission, which has an average of 67 days to act on a positive CHMP opinion, is expected to deliver its final decision in the second half of 2026.
The recommendation leans on three Phase 3 studies. BROADWAY and BROOKLYN each evaluated obicetrapib monotherapy and showed LDL-C reductions up to 40 percent versus placebo. TANDEM tested the combination with ezetimibe and produced reductions of approximately 50 percent versus placebo, both with tolerability profiles comparable to placebo. That tolerability point carries real clinical weight: the CETP inhibitor class has a troubled regulatory history, with Merck choosing not to file anacetrapib for approval in 2017 despite a positive Phase 3 signal, largely on commercial and risk-benefit grounds. Obicetrapib arrives as a low-dose, once-daily oral pill, which positions it for patients who already struggle with injectable regimens or statin intolerance, not as a replacement for high-intensity statins but as an add-on in a population where less than one in four ASCVD patients reaches an LDL-C goal below 70 mg/dL.
The commercial architecture is clear. Menarini holds exclusive European commercialization rights and is responsible for all regional regulatory interactions. NewAmsterdam collects tiered royalties in the low double-digits to mid-twenties on net sales, plus up to an additional 833 million euros in milestone payments tied to clinical, regulatory, and commercial achievements. That structure means NewAmsterdam’s near-term revenue in Europe is entirely contingent on Menarini’s launch execution, while NewAmsterdam focuses its own resources on the US and the ongoing PREVAIL cardiovascular outcomes trial, which completed enrollment of more than 9,500 patients in April 2024 and is designed to show obicetrapib reduces MACE in ASCVD patients on maximally tolerated lipid-modifying therapy.
The one number to watch from here is PREVAIL’s event-driven readout timeline. Regulatory approval in Europe and any eventual US filing will look substantially different depending on whether PREVAIL demonstrates a hard MACE reduction, not just LDL-C lowering. A positive outcomes signal transforms obicetrapib from a convenient add-on into a guideline-driven therapy; a neutral or ambiguous result keeps it confined to a niche despite the favorable lipid data already in hand.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
